Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Company profile
Ticker
PALI
Exchange
Website
CEO
Mr. J. D. Finley
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
WAI INC
SEC CIK
Corporate docs
Subsidiaries
Leading Biosciences, Inc. • Suzhou Neuralstem Biopharmaceutical Co., Ltd. ...
IRS number
522007292
PALI stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
27 Sep 24
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
8 Jul 24
ARS
2023 FY
Annual report to shareholders
22 May 24
DEFA14A
Additional proxy soliciting materials
22 May 24
DEF 14A
Definitive proxy
22 May 24
EFFECT
Notice of effectiveness
20 May 24
424B3
Prospectus supplement
17 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Departure of Directors or Certain Officers
10 May 24
Latest ownership filings
4
Binxian Wei
15 Jul 24
4
Margery B. Fischbein
15 Jul 24
4
Donald Allen Williams
15 Jul 24
4
Binxian Wei
12 Jun 24
4
Donald Allen Williams
12 Jun 24
4
Mitchell Lawrence Jones
30 May 24
4
John David Finley
30 May 24
4
Donald Allen Williams
29 May 24
4
John David Finley
28 May 24
4
John David Finley
22 May 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.38 mm | 11.38 mm | 11.38 mm | 11.38 mm | 11.38 mm | 11.38 mm |
Cash burn (monthly) | (no burn) | 420.83 k | 1.40 mm | 1.23 mm | 1.17 mm | 1.01 mm |
Cash used (since last report) | n/a | 1.58 mm | 5.27 mm | 4.64 mm | 4.38 mm | 3.78 mm |
Cash remaining | n/a | 9.80 mm | 6.11 mm | 6.74 mm | 7.00 mm | 7.60 mm |
Runway (months of cash) | n/a | 23.3 | 4.4 | 5.5 | 6.0 | 7.5 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 6.55 mm |
Total shares | 3.71 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Regional Medical Center Yuma | 2.25 mm | $5.55 mm |
Lind Global Fund II | 743.31 k | $543.00 k |
L1 Capital Global Opportunities Master Fund | 584.96 k | $456.00 k |
Intracoastal Capital | 131.09 k | $0.00 |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jul 24 | Williams Donald Allen | Common Stock | Grant | Acquire A | No | No | 4.49 | 2,100 | 9.43 k | 2,100 |
11 Jul 24 | Margery B. Fischbein | Common Stock | Grant | Acquire A | No | No | 4.49 | 2,100 | 9.43 k | 2,100 |
11 Jul 24 | Wei Binxian | Common Stock | Grant | Acquire A | No | No | 4.49 | 2,100 | 9.43 k | 2,100 |
11 Jun 24 | Williams Donald Allen | Comon Stock, par value $0.01 | Option exercise | Acquire M | No | No | 0 | 340 | 0.00 | 340 |
11 Jun 24 | Wei Binxian | Comon Stock, par value $0.01 | Option exercise | Acquire M | No | No | 0 | 465 | 0.00 | 467 |
News
Health Canada Clears Palisade Bio To Commence Phase 1 Clinical Study for Lead Program, PALI-2108 For Treatment Of Ulcerative Colitis
10 Oct 24
Palisade Bio Provides Update On Progress Toward Launch Of Phase 1 Human Clinical Study For Lead Program, PALI-2108 For The Treatment Of Ulcerative Colitis; On Track Towards Clinical Site Initiation And Dosing Of First Patient In Phase 1 Human Clinical Study Before Year End
25 Sep 24
Palisade Bio Launches New Corporate Branding And Reiterates Commitment To Advancing Next-Generation Precision Therapies, Remains Committed To Its Mission To Become A Leader In Developing Differentiated Product Candidates Targeting Immune, Inflammatory And Fibrotic Diseases
16 Sep 24
Palisade Bio Presents Data Demonstrating PDE4B Expression In Patient Cohorts Could Be Utilized As A Potential Marker For Patient Stratification
5 Sep 24
Palisade Bio Q2 2024 GAAP EPS $(3.32) Misses $(3.11) Estimate
13 Aug 24
Press releases
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting
15 Oct 24
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
10 Oct 24
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
8 Oct 24
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
25 Sep 24
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
5 Sep 24